DOCSLIB.ORG

Supplementary Information 0103 - 5053 $6.00+0.00 SI in Silico Antibacterial Activity Modeling Based on the TOMOCOMD-CARDD Approach Juan A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Information 0103 - 5053 $6.00+0.00 SI in Silico Antibacterial Activity Modeling Based on the TOMOCOMD-CARDD Approach Juan A J. Braz. Chem. Soc., Vol. 26, No. 6, S1-S38, 2015. Printed in Brazil - ©2015 Sociedade Brasileira de Química Supplementary Information 0103 - 5053 $6.00+0.00 SI In silico Antibacterial Activity Modeling Based on the TOMOCOMD-CARDD Approach Juan A. Castillo-Garit,a,b,c Yovani Marrero-Ponce,b,c,d,e Stephen J. Barigye,*,f Ricardo Medina-Marrero,b,g Milagros G. Bernal,b,g José M. G. de la Vega,h Francisco Torrens,c Vicente J. Arán,i Facundo Pérez-Giménez,d Ramón García-Domenechd and Rosa Acevedo-Barriose aCentro de Estudio de Química Aplicada, Facultad de Química-Farmacia, Universidad Central “Marta Abreu” de Las Villas, 54830 Santa Clara, Villa Clara, Cuba bComputer-Aided Molecular “Biosilico” Discovery and Bioinformatic Research International Network (CAMD-BIR International Network), Los Laureles L76MD, Nuevo Bosque, 130015 Cartagena de Indias, Bolivar, Colombia cInstitut Universitari de Ciència Molecular, Universitat de València, Edifici d’Instituts de Paterna, Poligon la Coma s/n, E-46980, Paterna, Spain dUnidad de Investigación de Diseño de Fármacos y Conectividad Molecular, Departamento de Química Física, Facultad de Farmacia, Universitat de València, 46100 València, Spain eGrupo de Investigación en Estudios Químicos y Biológicos, Facultad de Ciencias Básicas, Universidad Tecnológica de Bolívar, 130010 Cartagena de Indias-Bolívar, Colombia fDepartamento de Química, Universidade Federal de Lavras, 3037, 37200-000 Lavras-MG, Brazil gChemical Bioactive Center, Department of Microbiology, Central University of Las Villas, 54830, Santa Clara-Villa Clara, Cuba hDepartamento de Química Física Aplicada, Facultad de Ciencias, Universidad Autónoma de Madrid, 28049, Madrid, Spain iInstituto de Química Médica, CSIC, c/ Juan de la Cierva 3, 28006, Madrid, Spain Table S1. Random, but not exhaustive, sample of the molecular families of antibacterial agents studied here *e-mail: [email protected] S2 In silico Antibacterial Activity Modeling Based on the TOMOCOMD-CARDD Approach J. Braz. Chem. Soc. Table S2. Results of the classification of active compounds in the training sets Active compounds DP% a Active compounds DP% a name Non-stoc. Stoc. name Non-stoc. Stoc. Mefuralazine 50.55 77.87 Pentisomicin 78.24 71.98 Cryptargol 18.44 –8.10 Betamicin sulfate 88.37 83.59 Arsylen –32.88 –82.20 Argenti fluoresceinas –25.12 –29.86 Fosfomycin –51.44 –23.58 Ftalil-medeyol 86.95 82.49 Taurultam 3.39 –23.00 Nidulin 5.56 28.02 Emimycin –36.72 –37.87 Chloramphenicol monocinnamate 55.98 74.62 Mepartricin A 99.59 99.12 Cefalonium 84.78 87.40 Azaserine 11.66 24.76 Thiatetracycline 61.92 56.92 Nibroxane –17.37 –2.44 Cefodizine 99.30 99.38 Phosphinothricin –25.52 –7.91 Solupyridine 99.64 98.96 Furidiazina 43.63 69.20 Ceforanide 97.35 98.54 Fluoramphenicol 24.29 44.81 Vanyldisulfamide 97.55 92.13 F-8 40.10 59.97 Cefuroxime axetil 96.86 95.45 Iodosil-tabl 48.81 33.65 Butampicillin 42.20 49.77 Furaguanidine 30.15 58.34 Azlocillin sodium 91.80 90.11 Protoxyl 13.05 –81.80 Prodigiosin –54.64 –54.58 Sulfanilamide 15.35 –3.11 Annvithrin 12.57 9.45 Bismuth cevitamate –24.17 –25.72 Andrographolide sodium bisulfite 60.92 40.22 Docitrol 23.37 13.04 Etisomicin 78.11 79.47 Parabortine 21.67 45.96 Micronomicin 75.10 56.46 Allicin –83.43 –43.61 Nitrocefin 92.37 97.93 Diamide –15.16 –49.56 Cefoxazole 85.10 90.67 Cupri gluconas –2.21 –7.20 Sodium diphenicillin 23.37 29.21 Desderman –12.29 9.67 Demecloxycline 70.85 68.26 Dibromsalicylamide –17.09 –5.16 Furampicillin 57.25 63.99 Demethylthiolutin –49.64 31.05 Fumoxicillin sodium 70.30 76.27 Nifuraldezone 49.78 70.07 Nafcillin sodium 39.73 42.99 Sulcimid 44.53 36.47 Sancycline 48.01 33.01 Nihydrazone –0.11 34.81 Demecycline 62.10 51.13 Planomycin 11.50 13.49 BL-S339 95.65 96.32 Sulfamerazine 56.01 59.24 Palmatine –52.94 –83.05 Sulfathiourea 70.06 56.08 Lenampicillin hydrochloride 85.15 83.71 Sulfacarbamide 63.87 50.84 Aristoplomb 99.78 99.47 Mafenide 12.14 –9.72 Mezlocillin sodium 99.12 98.17 Aldanil 61.65 62.69 Sarmoxicillin 67.34 59.75 Mesulfamide sodium 90.78 75.80 Bacampicillin 84.82 82.10 Sulfaguanidina 63.81 54.33 Aspoxicillin 93.83 91.95 Nifurthiazole 50.61 71.29 Pivmecillinam 52.44 48.66 Nitrofurantoin 50.70 70.61 Bluensomycin 99.09 98.15 Furazolidone 22.09 48.47 Hidroxystreptomycin 99.42 98.93 Sulfathiadiazole 82.10 57.10 Netilmicin sulfate 76.59 68.35 Nifuradene 24.10 52.03 Apramycin 95.16 93.06 Methylacetopyronone –48.73 –48.88 Butirosin 95.57 94.40 Fumigatin –58.01 –64.59 Dihydrodesoxyestreptomycin 98.64 97.55 Spinulosin –41.41 –48.95 Erythromycin acetate 92.63 81.98 Sulfacetamide 41.58 28.49 Propikacin 96.59 95.71 Glycylsulfanilamide 55.92 33.20 Lavendamycin 42.15 60.02 Nidroxyzone 43.98 65.55 Actamycin 77.60 80.64 Sulfaperin 59.01 55.49 Talmetoprim 47.12 22.70 Pentizidone sodium –40.33 –33.22 Cefsulodin sodium 98.45 97.53 Septosil 91.34 78.95 Meclocycline 70.85 68.38 Sulfamethoxydiazine 65.29 58.14 Cetocycline hydrochloride 32.41 43.36 Vol. 26, No. 6, 2015 Castillo-Garit et al. S3 Table S2. Results of the classification of active compounds in the training sets (cont.) Active compounds DP% a Active compounds DP% a name Non-stoc. Stoc. name Non-stoc. Stoc. Rifabutin 95.54 94.15 Timoxicillin sodium 88.79 91.58 Broxyquinoline –83.23 1.58 Fenbenicillin potassium 41.29 46.96 Clioquinol –97.01 –2.66 Ticarcillin cresyl sodium 73.44 78.38 Chloroxine –63.76 –31.84 Forbisen –16.75 –13.73 Diiodohydroxyquinoline –24.38 –23.66 Furbenicillin 91.32 90.92 Korinal –52.09 –17.08 Cefpirome 93.88 94.50 Nitroxoline –38.90 –17.25 Ceftazidime 97.95 98.53 Binoxol –76.43 –77.31 Bromtetracycline 77.93 72.63 Bactofuril 40.65 62.80 Tetracycline 63.23 52.71 Furacril 14.74 60.60 Doxycycline 62.10 50.86 Furalazine 23.08 68.35 Oxytetracycline 73.92 66.53 Captan 30.14 49.10 Dithyral –32.72 –18.97 Phenolsufazole 88.49 51.88 Metioxate hydrochloride 36.01 16.59 Melarsenoxyd 31.78 39.53 W 1889 19.02 23.51 Sulfathiazole 66.72 55.46 Pivampicillin hydrochloride 77.14 72.29 Furazoliumchloride 16.76 41.35 Cefbuperazone sodium 99.74 99.68 Furmethoxadone 23.86 52.32 Penethacilline 33.66 32.79 Aureothricin –56.14 10.67 Pleuromulin –38.70 –40.17 Sulfametrole 67.64 83.23 UTH 31 –56.92 –61.94 Nifurimide 25.63 55.00 Amikacin sulfate 98.18 97.72 Melarsen 84.32 59.18 Butikacin 96.62 95.81 Showdomycin 5.40 3.66 Carfecillin sodium 63.75 64.71 Minimycin 31.28 23.37 Propampicillin 57.25 63.99 Sulgin ASG 77.25 67.86 Sulfamazone sodium 99.35 98.67 Anticapsin –32.92 –33.06 Clomocycline 78.71 73.32 Sulfalene 65.02 57.80 Sulfoxyl-salvarsan 73.07 83.34 Dimethylhomosulfamin 3.94 –31.79 Cefaclomezine 89.03 81.65 Chlorozotocin 60.87 75.69 Piperacillin sodium 94.35 93.48 Negamycin 30.33 13.56 Vaneprim 94.32 85.02 Thiocarbarsone 75.92 23.39 Domigon 54.62 28.34 Chlorquinaldol –64.96 –36.23 Framycetin 98.69 98.44 Tilbroquinol –66.85 –54.29 Neomycin C 98.69 98.44 Tiodonium chloride –23.33 –42.53 Talampicillin hydrochloride 75.77 76.16 Dipyrithione –6.52 48.22 Pirbenicillin sodium 90.01 91.69 Akritoin 50.70 70.60 Galactosulfonum 96.91 96.14 Sulfachlorpyridazine 69.67 66.58 PANS 61.32 47.43 Sulfaclozine sodium 60.27 61.75 Glucosulfone 99.99 99.96 Lavulino-INH –8.88 5.49 Stearylsulfamide 41.58 28.56 Rifordin 93.83 92.54 Cefpiramide sodium 98.82 99.40 Miran 17.55 55.48 Fuzlocillin 97.44 97.83 Sulfiodizole 74.67 77.54 Cefoperazone sodium 99.30 99.46 Mequidox –27.63 –44.03 Formo-sulfamerazine 99.58 99.54 Dioxidine –9.86 –29.12 Glycinemethyltetracycline 89.10 80.63 Sulfamidomaleyl 73.73 57.74 Sultamicillin 98.94 98.38 Amifenozin –15.13 –8.59 Methymycin 15.37 –9.39 Sulfadiazine 47.44 61.75 Neomethymycin 13.54 –11.78 Butarsen –62.85 –77.00 Capreomycin 1A 99.95 99.89 Sulfamoxole 61.55 54.77 Cuprimycin 98.59 92.78 Methylsulfathiazole 64.15 59.28 Carindacillin sodium 63.75 64.71 Sulfamethoxazole 52.74 56.19 Fibracillin 81.37 86.06 Sulfasuccinamide 73.73 56.75 Khinoin –1.47 –16.15 Soluseptamid 80.35 65.07 Plauracin 72.25 73.62 S4 In silico Antibacterial Activity Modeling Based on the TOMOCOMD-CARDD Approach J. Braz. Chem. Soc. Table S2. Results of the classification of active compounds in the training sets (cont.) Active compounds DP% a Active compounds DP% a name Non-stoc. Stoc. name Non-stoc. Stoc. Sulfaethidole 80.80 68.91 Mupirosin 39.21 29.52 Sulfatrozole 68.64 87.42 Kanchanomycin 60.23 55.05 Nifurdazil 37.07 61.09 Disulformin 99.98 99.91 Sch 29482 19.35 30.85 Piroxicillin sodium 99.87 99.85 Cordycepin 23.41 46.14 Rolitetracycline 69.98 55.84 Sulfatroxazole 52.74 56.02 Morphocyclin 76.65 61.15 Sulfafurazole 56.12 42.36 Chloramphenicol palmitate 55.98 74.55 Alfasol 97.25 94.33 Steffimycin 79.72 58.86 Nifurethazone 38.55 43.98 Streptomycin B 99.88 99.77 Bismuti camsilas 6.95 –14.42 Cefpimizole sodium 99.78 99.61 Linatine 38.74 40.28 Prolinomethyltetracycline 88.57 81.55 Cloxiquine acetate –71.26 –43.21 Virginiamycin M1 72.00 70.86 Nifurpyrimidine 4.84 49.11 E 702 99.84 99.92 Nitrofurfurylideneisoniazid 19.07 57.26 Superciclin ‘farmabion’ 81.55 77.87 Sulfatriazine 86.06 77.40 Meglucycline 95.85 92.94 Plumbagin –67.85 –64.40 Pipacycline 83.47 71.74 Nifurvidine –0.15 45.13 Guamecycline hydrochloride 97.70 95.32 Nitrosulfapyridine 61.22 72.43 Amicetin 96.03 92.84 Carbadox 65.53 65.31 Chloramphenicol stearate 55.98 74.55 Nifurmazole 61.66 76.60 Lividomycin 99.69 99.61 Sulfapyridine 36.62 34.77 Luteoskyrin 82.79 87.63 Pyridinin 36.89 40.14 Aklavin 66.79 39.35 Tiogin 58.77 64.93 Apicycline 94.19 89.70 Tevenel 82.40 76.81 Sulfacholazine 85.40 82.48 Sulfadicramide 45.84 12.01 Chloramphenicol stearoylglycolate 80.45 87.62 Sulfathylpyrazole 55.51 38.51 Fusidic acid –11.60 –13.03 m-Methoxythioacetazone
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • A Small Outbreak of Third Generation Cephem-Resistant Citrobacter
    Jpn. J. Infect. Dis., 57, 2004 Laboratory and Epidemiology Communications A Small Outbreak of Third Generation Cephem-Resistant Citrobacter freundii Infection on a Surgical Ward Toshi Nada*, Hisashi Baba, Kumiko Kawamura2, Teruko Ohkura, Keizo Torii1 and Michio Ohta1 Department of Clinical Laboratory, Nagoya University Hospital, Nagoya 466-8560, 1Department of Bacteriology, Nagoya University Graduate School of Medicine, Nagoya 466-8550 and 2Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya 461-8673 Communicated by Yoshichika Arakawa (Accepted June 11, 2004) Citrobacter freundii is a member of family Enterobacteri- from those of type a and b strains. aceae and has been associated with nosocomial infections As previous studies have indicated, third generation in the urinary, respiratory, and biliary tracts of debilitated cephem-resistance of Gram-negative bacteria are due to the hospital patients. C. freundii has an inducible chromosomally hydrolysis of β-lactams by β-lactamases. These β-lactamases encoded cephalosporinase that can inactivate cephamycins include extended spectrum β-lactamase (ESBL), metallo- and cephalosporins. However, most clinical isolates are β-lactamase, and plasmid-encoded AmpC cephalosporinase sensitive to new third generation cephems and carbapenems. (1-3). ESBL confers variable levels of resistance to cefotaxime, We report here a small outbreak of infection caused by ceftazidime, and other broad-spectrum cephalosporins and third generation cephem-resistant C. freundii on a surgical to monobactams, but has no detectable activity against ward of a university hospital in 2002. We identified four cephamycins and carbapenems, and is relatively sensitive patients with biliary infection and two carrier patients during to sulbactam (1). Plasmid-encoded metallo-β-lactamase July and October.
    [Show full text]
  • Sepsis Caused by Newly Identified Capnocytophaga Canis Following Cat Bites: C
    doi: 10.2169/internalmedicine.9196-17 Intern Med 57: 273-277, 2018 http://internmed.jp 【 CASE REPORT 】 Sepsis Caused by Newly Identified Capnocytophaga canis Following Cat Bites: C. canis Is the Third Candidate along with C. canimorsus and C. cynodegmi Causing Zoonotic Infection Minami Taki 1, Yoshio Shimojima 1, Ayako Nogami 2, Takuhiro Yoshida 1, Michio Suzuki 3, Koichi Imaoka 3, Hiroki Momoi 1 and Norinao Hanyu 1 Abstract: Sepsis caused by a Capnocytophaga canis infection has only been rarely reported. A 67-year-old female with a past medical history of splenectomy was admitted to our hospital with fever and general malaise. She had been bitten by a cat. She showed disseminated intravascular coagulation and multi-organ failure because of severe sepsis. On blood culture, characteristic gram-negative fusiform rods were detected; therefore, a Capnocytophaga species infection was suspected. A nucleotide sequence analysis revealed the species to be C. canis, which was newly identified in 2016. C. canis may have low virulence in humans; however, C. canis with oxidase activity may cause severe zoonotic infection. Key words: Capnocytophaga canis, Capnocytophaga canimorsus, sepsis, oxidase activity (Intern Med 57: 273-277, 2018) (DOI: 10.2169/internalmedicine.9196-17) Introduction Case Report The genus Capnocytophaga consists of gram-negative A 67-year-old woman was admitted to our hospital with rod-shaped bacteria that reside in the oral cavities of humans general malaise and fever for 3 days starting the day after and domestic animals. Capnocytophaga formerly comprised being bitten by a cat on both her hands. She had a medical eight species (1, 2).
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • B-Lactams: Chemical Structure, Mode of Action and Mechanisms of Resistance
    b-Lactams: chemical structure, mode of action and mechanisms of resistance Ru´ben Fernandes, Paula Amador and Cristina Prudeˆncio This synopsis summarizes the key chemical and bacteriological characteristics of b-lactams, penicillins, cephalosporins, carbanpenems, monobactams and others. Particular notice is given to first-generation to fifth-generation cephalosporins. This review also summarizes the main resistance mechanism to antibiotics, focusing particular attention to those conferring resistance to broad-spectrum cephalosporins by means of production of emerging cephalosporinases (extended-spectrum b-lactamases and AmpC b-lactamases), target alteration (penicillin-binding proteins from methicillin-resistant Staphylococcus aureus) and membrane transporters that pump b-lactams out of the bacterial cell. Keywords: b-lactams, chemical structure, mechanisms of resistance, mode of action Historical perspective Alexander Fleming first noticed the antibacterial nature of penicillin in 1928. When working with Antimicrobials must be understood as any kind of agent another bacteriological problem, Fleming observed with inhibitory or killing properties to a microorganism. a contaminated culture of Staphylococcus aureus with Antibiotic is a more restrictive term, which implies the the mold Penicillium notatum. Fleming remarkably saw natural source of the antimicrobial agent. Similarly, under- the potential of this unfortunate event. He dis- lying the term chemotherapeutic is the artificial origin of continued the work that he was dealing with and was an antimicrobial agent by chemical synthesis [1]. Initially, able to describe the compound around the mold antibiotics were considered as small molecular weight and isolates it. He named it penicillin and published organic molecules or metabolites used in response of his findings along with some applications of penicillin some microorganisms against others that inhabit the same [4].
    [Show full text]
  • Deanxit SPC.Pdf
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Deanxit film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Flupentixol 0.5 mg (as 0.584 mg flupentixol dihydrochloride) Melitracen 10 mg (as 11.25 mg melitracen hydrochloride) Excipients with known effect: Lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets. Round, biconvex, cyclamen, film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Anxiety Depression Asthenia. Neurasthenia. Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts. 4.2 Posology and method of administration Posology Adults Usually 2 tablets daily: morning and noon. In severe cases the morning dose may be increased to 2 tablets. The maximum dose is 4 tablets daily. Older people (> 65 years) 1 tablet in the morning. In severe cases 1 tablet in the morning and 1 at noon. Maintenance dose: Usually 1 tablet in the morning. SPC Portrait-REG_00051968 20v038 Page 1 of 10 In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended. Paediatric population Children and adolescents (<18 years) Deanxit is not recommended for use in children and adolescents due to lack of data on safety and efficacy. Reduced renal function Deanxit can be given in the recommended doses. Reduced liver function Deanxit can be given in the recommended doses. Method of administration The tablets are swallowed with water. 4.3 Contraindications Hypersensitivity to flupentixol and melitracen or to any of the excipients listed in section 6.1.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]